Amarin Corp Plc (AMRN)

[Bouf]

The good news is that the generics will have to rely heavily on Mori in their brief, so this will open this up for argument by Amarin in reply, provided there is someplace in the trial record where the statistical issue with the Mori study was raised at trial.

Trial counsel must have raised the statistical issue at trial, no? I’m going to go back and check the post -trial briefs.